EPI-Q Inc.
University of Utah.
J Affect Disord. 2020 Oct 1;275:299-306. doi: 10.1016/j.jad.2020.07.014. Epub 2020 Jul 10.
Shared decision-making (SDM) involves patients and clinicians choosing treatment jointly. SDM in mental health is hampered by lack of well-developed supporting tools. We describe an evidence-based patient decision aid (PDA) to facilitate SDM for treatment-resistant depression (TRD) following US National Quality Forum standards which are based upon the International Patient Decision Aid Standards (IPDAS).
A web-based PDA was developed by a multidisciplinary steering committee of clinicians, patient advocates, patients and a decision scientist. Development included creating content consistent with decision-making domains that are impacted by patient preference in TRD. Development was guided by literature review, group conference calls/discussions, patient and clinician interviews (N = 8), high and lower literacy focus groups (N = 11) and pilot study (N = 5). The PDA presents risk-benefit information on domains (e.g., effectiveness, mode of administration, side effects, cost) and includes values clarification exercises. Pilot study patients were administered the Decisional Conflict Scale (DCS) and Decision Self-Efficacy Scale (DSES) prior to and following PDA interaction and clinician SDM.
During the pilot, prior to PDA interaction, mean (standard deviation) DCS score was 42.2 (14.4) and DSES score was 86.0 (14.6) out of 100. Following PDA interaction and SDM, DCS decreased (improved) to 28.1 (SD 4.1) and DSES increased to 95.5 (6.7). All patients endorsed that the PDA helped them to: recognize pros and cons of options; understand how treatments were administered, possible side-effects, and likelihood of benefit; recognize what was important relative to the decision; organize thoughts and prepare for a discussion with their clinician.
This PDA may support SDM in TRD. A future trial to determine impact of the present SMD on decision-making quality is warranted. It also highlights gaps in comparative effectiveness trials that could guide equitable shared decision-making.
共同决策(SDM)涉及患者和临床医生共同选择治疗方案。由于缺乏完善的支持工具,精神健康领域的 SDM 受到阻碍。我们根据基于国际患者决策辅助标准(IPDAS)的美国国家质量论坛标准,描述了一种有助于治疗抵抗性抑郁症(TRD)的基于证据的患者决策辅助工具(PDA)。
一个由临床医生、患者倡导者、患者和决策科学家组成的多学科指导委员会开发了一个基于网络的 PDA。开发包括创建与受患者偏好影响的 TRD 决策领域一致的内容。开发过程由文献回顾、小组电话会议/讨论、患者和临床医生访谈(N=8)、高和低文化程度焦点小组(N=11)和试点研究(N=5)指导。PDA 提供有关领域的风险效益信息(例如,有效性、给药方式、副作用、成本),并包括价值观澄清练习。在试点研究中,患者在使用 PDA 之前和之后进行了决策冲突量表(DCS)和决策自我效能量表(DSES)的测试,同时还进行了临床医生的 SDM。
在试点期间,在使用 PDA 之前,DCS 的平均(标准差)得分为 42.2(14.4),DSES 的得分为 100 分中的 86.0(14.6)。在使用 PDA 进行交互和 SDM 后,DCS 降低(改善)至 28.1(SD 4.1),DSES 增加至 95.5(6.7)。所有患者都表示,PDA 帮助他们:认识到选择的利弊;了解治疗方法、可能的副作用和获益的可能性;认识到与决策相关的重要因素;整理思路并为与临床医生的讨论做好准备。
该 PDA 可能支持 TRD 的 SDM。未来有必要进行一项确定当前 SMD 对决策质量影响的试验。它还突出了比较有效性试验中的差距,这可以指导公平的共同决策。